MMIT Reality Check on Macular Edema (Jan 2021)

According to our recent payer coverage analysis for macular edema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for macular edema treatments shows that under the pharmacy benefit, almost 37% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In August 2019, the FDA granted approval to Eylea (aflibercept) as a prefilled syringe. It remains available in the original single-dose vial for which it was approved in November 2011. The Regeneron Pharmaceuticals, Inc. product is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

May 13

MMIT Reality Check on Narcolepsy

Read More
nurse-doing-blood-test
May 6

MMIT Reality Check on Hemophilia B (Factor IX)

Read More
April 29

MMIT Reality Check on Anemia Due to Chronic Kidney Disease

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today